Development of selective inhibitors of necrosis

Chemical Record

Volumn 10, Issue 5, 2010, Pages 308-314

  Sodeoka, Mikiko ^a   Riken, Kosuke Dodo ^b  

^a Institute of Physical and Chemical Research   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Apoptosis; Cell death; Indolylmaleimide; Necrosis; Oxidative stress

Indexed keywords

2 (1 (3 AMINOPROPYL)INDOL 3 YL) 3 (INDOL 3 YL) N METHYLMALEIMIDE; 2 (1H INDOL 3 YL) 3 PENTYLAMINO MALEIMIDE; 2-(1-(3-AMINOPROPYL)INDOL-3-YL)-3-(INDOL-3-YL)-N-METHYLMALEIMIDE; 2-(1H-INDOL-3-YL)-3-PENTYLAMINO-MALEIMIDE; CARDIOTONIC AGENT; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; NECROSIS; OXIDATIVE STRESS; PATHOLOGY; REPERFUSION INJURY;

CARDIOTONIC AGENTS; HUMANS; INDOLES; MALEIMIDES; NECROSIS; OXIDATIVE STRESS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRROLES; REPERFUSION INJURY;

EID: 78649433883     PISSN: 15278999     EISSN: 15280691     Source Type: Journal    
DOI: 10.1002/tcr.201000031     Document Type: Article

References (25)

1. N. Tolliday, P. A. Clemons, P. Ferraiolo, A. N. Koehler, T. A. Lewis, X. Li, S. L. Schreiber, D. S. Gerhard, S. Eliasof, Cancer Res. 2006, 66, 8935-8942.
2. a) J. Liu, J. D. Farmer Jr., W. S. Lane, J. Friedman, I. Weissman, S. L. Schreiber, Cell, 1991, 66, 807-815;.
3. b) S. L. Schreiber, G. R. Crabtree, Immunol. Today 1992, 13, 136-42.
4. a) D. R. Green, J. C. Reed, Science, 1998, 281, 1309-1312.
5. b) D. Spierings, G. McStay, M. Saleh, C. Bender, J. Chipuk, U. Maurer, D. Green, Science, 2005, 310, 66-67.
6. J. F. R. Kerr, A. H. Wyllie, A. R. Currie, Br. J. Cancer 1972, 26, 239-257.
7. a) N. A. Thornberry, Y. Lazebnik, Science 1998, 281, 1312-1316.
8. b) S. B. Bratton, M. MacFarlane, K. Cain, G. M. Cohen, Exp. Cell. Res. 2000, 256, 27-33.
9. a) P. Golstein, G. Kroemer, Trends Biochem. Sci. 2007, 32, 37-43.
10. b) L. Galluzzi, G. Kroemer, Cell 2008, 135, 1161-1163.
11. a) J. Yuan, M. Lipinski, A. Degterev, Neuron 2003, 40, 401-413.
12. b) P. Nicotera, M. Leist, L. Manzo, Trends Pharmacol. Sci. 1999, 20, 46-51;.
13. c) P. Saikumar, Z. Dong, J. M. Weinberg, M. A. Venkatachalam, Oncogene 1998, 17, 3341-3349.
14. K. Dodo, M. Katoh, T. Shimizu, M. Takahashi, M. Sodeoka, Bioorg. Med. Chem. Lett. 2005, 15, 3114-3118.
15. Katoh, M.; Dodo, K.; Fujita, M.; Sodeoka, M. Bioorg. Med. Chem. Lett. 2005, 15, 3109-3113.
16. R. Asakai, Y. Aoyama, T. Fujimoto, Neurosci. Res., 2002, 44, 297-304.
17. D. Toullec, P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. Baudet, P. Boissin, E. Boursier, F. Loriolle, L. Duhamel, D. Charon, J. Kirilovsky, J. Biol. Chem. 1991, 266, 15771-15781.
18. S. P. Davies, H. Reddy, M. Caivano, P. Cohen, Biochem. J. 2000, 351, 95-105.
19. a) L. Prade, R. A. Engh, A. Girod, V. Kinzel, R. Huber, D. Bossemeyer, Structure, 1997, 5, 1627-1637.
20. b) A. M. Lawrie, M. E. Noble, P. Tunnah, N. R. Brown, L. N. Johnson, J. A. Endicott, Nat. Struct. Biol. 1997, 4, 796-801.
21. c) Recently, the crystal structure of PKC(-BM I complex has been solved, and two critical hydrogen bonds between maleimide carbonyl/NH and ATP binding site were found. See: A. Messerschmidt, S. Macieira, M. Velarde, M. Bädeker, C. Bebda, A. Jestel, H. Brandstetter, T. Neuefeind, M. Blaesse, J. Mol. Biol. 2005, 352, 918-931.
22. a) R. G. Katare, Z. Zhitian, M. Sodeoka, S. Sasaguri, Transplantation 2007, 83, 1588-1594.
23. b) R. G. Katare, Z. Zhitian, M. Sodeoka, S. Sasaguri, Can. J. Physiol. Pharmacol. 2007, 85, 979-985.
24. K. Dodo, M. Fujita, M. Katoh, M. Sodeoka, unpublished results.
25. M. Fujita, M. Katoh, Y. Aoyama, R. Asakai, M. Sodeoka, unpublished results.